Akari Therapeutics plc
Organization details
- Legal name
- Akari Therapeutics plc
- Former names
- Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Year founded
- 2004
- Jurisdiction of incorporation
- United Kingdom
- Headquarters city
- Tampa
- Headquarters state / province
- Florida
- Headquarters country
- United Kingdom
- Fiscal year end
- December
- Ticker symbol
- AKTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001541157
- EIN
- 98-1034922
- UK company number
- 05252842
Board of directors
-
Abizer Gaslightwala · Director · CEOSince 2024
-
Abizer Gaslightwala · DirectorSince 2024
-
Donald A. Williams · DirectorSince 2024
-
Hoyoung Huh · DirectorSince 2024
-
Hoyoung Huh · DirectorSince 2024
-
James R. Neal · DirectorSince 2024
-
Michael Grissinger · DirectorSince 2024
-
Mohamed Wa'el Ahmed Hashad · DirectorSince 2024
-
Rachelle Suzanne Jacques · Director · Chief Executive OfficerSince 2024
-
Raymond Prudo-Chlebosz · DirectorSince 2024
-
Raymond, Prudo-Chlebosz · DirectorSince 2015
-
Robert B. Bazemore · DirectorSince 2024
-
Robert Bazemore · DirectorSince 2024
-
Samir Rashmikant Patel · DirectorSince 2024
-
Samir Rashmikant Patel · DirectorSince 2023
-
Sandip I. Patel · DirectorSince 2024
-
Sandip Patel · DirectorSince 2024
Former directors
-
Allan Lee Shaw · Director2013 – 2016
-
Amos Eiran · Director2012 – 2015
-
Clive Stuart Richardson · Director2015 – 2022
-
David Anthony Byrne · Director2016 – 2023
-
David Horn Solomon · Director2017 – 2018
-
David, Sidransky · Director2007 – 2015
-
Donald Allen Williams · Director2016 – 2024
-
Gur-Arye Yehuda, Roshwalb · Director2014 – 2017
-
James Ferguson, Hill · Director2015 – 2023
-
James Neal · Director2024 – 2026
-
Johnson, Lau · Director2007 – 2015
-
Mark Cohen · Director2004 – 2016
-
Michael Grissinger · Director2018 – 2024
-
Mohamed Wa’El Ahmed Hashad · Director2023 – 2024
-
Peter, Doctor Feldschreiber · Director2018 – 2022
-
Rachelle Suzanne Jacques · Director2022 – 2024
-
Robert Eugene Ward · Director2016 – 2018
-
Robert Francis Doman · Director2013 – 2015
-
Stuart Charles Ungar · Director2015 – 2023
Chief executives
Board connections
7 of this board's directors also sit on 12 other boards. 11 are in the same sector.
-
Adicet Bio Inc. Same sectorvia Michael Grissinger
-
Aprea Therapeutics Inc. Same sectorvia Michael Grissinger
-
Ardelyx Inc. Same sectorvia Robert B. Bazemore
- via Sandip I. Patel
-
Corbus Pharmaceuticals Holdings Inc. Same sectorvia Rachelle Suzanne Jacques
-
Lipocine Inc. Same sectorvia Michael Grissinger
-
Longeveron Inc. Same sectorvia Mohamed Wa'el Ahmed Hashad
-
Nuvation Bio Inc. Same sectorvia Robert B. Bazemore
-
Palisade Bio Inc. Same sectorvia James R. Neal
-
Pliant Therapeutics Inc. Same sectorvia Hoyoung Huh
-
Processa Pharmaceuticals Inc. Same sectorvia James R. Neal
-
uniQure N.V. Same sectorvia Rachelle Suzanne Jacques
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 14, 2026 | Abizer Gaslightwala Director, Officer (CEO) | Option exercise | +19,333 | $0.00 | $8 |
| Oct 14, 2026 | Abizer Gaslightwala Director, Officer (CEO) | Option exercise | +7,733 | $0.00 | $3 |
| Oct 14, 2026 | Robert B. Bazemore Director | Option exercise | +773 | $0.00 | $0 |
| Oct 14, 2026 | Sandip I. Patel Director | Option exercise | +3,866 | $0.00 | $2 |
| Oct 14, 2026 | Robert B. Bazemore Director | Option exercise | +3,093 | $0.00 | $1 |
| Oct 14, 2026 | Sandip I. Patel Director | Option exercise | +6,186 | $0.00 | $2 |
| Oct 5, 2026 | Samir Rashmikant Patel Director | Grant or award | +2,236 | $7.90 | $17,662 |
| Oct 5, 2026 | Robert B. Bazemore Director | Grant or award | +4,677 | $7.90 | $36,944 |
| Oct 5, 2026 | Sandip I. Patel Director | Grant or award | +4,313 | $7.90 | $34,068 |
| Oct 5, 2026 | Hoyoung Huh Director, 10% owner | Grant or award | +6,160 | $7.90 | $48,658 |
| Oct 5, 2026 | Raymond Prudo-Chlebosz Director | Grant or award | +3,240 | $7.90 | $25,593 |
| Sep 29, 2026 | Abizer Gaslightwala Director, Officer (CEO) | Grant or award | +6,430 | $9.72 | $62,500 |
| Aug 18, 2026 | Samir Rashmikant Patel Director | Grant or award | +6,300 | $7.90 | $49,764 |
| Aug 18, 2026 | Robert B. Bazemore Director | Grant or award | +13,100 | $7.90 | $103,477 |
| Aug 18, 2026 | Sandip I. Patel Director | Grant or award | +12,100 | $7.90 | $95,578 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Akari Therapeutics plc
Who is the CEO of Akari Therapeutics plc?
Rachelle Suzanne Jacques has been Akari Therapeutics plc's Chief Executive Officer since January 2024.
How many directors are on Akari Therapeutics plc's board?
Akari Therapeutics plc's board has 17 directors: Abizer Gaslightwala, Abizer Gaslightwala, Donald A. Williams, Hoyoung Huh, Hoyoung Huh, James R. Neal, Michael Grissinger, Mohamed Wa'el Ahmed Hashad, Rachelle Suzanne Jacques, Raymond Prudo-Chlebosz and 7 others.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="akari-therapeutics-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.